Give and Takeda
23 April 2018
Email
Share
The Japanese drugmaker led by a French CEO added cash to a slightly sweeter $60 bln bid for Irish rival Shire. Takeda’s target is cheap, but the big premium will be hard to justify. The deal also would flood the market with shares and ratchet up debt. It’s all a big stretch.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.